Obstructive Sleep Apnea is Highly Prevalent in Hypertrophic Cardiomyopathy and Independently Worsens Disease Outcomes
OSA affects 55-70% of patients with HCM and is independently associated with increased symptom burden, worse cardiac remodeling, greater myocardial fibrosis, and higher rates of atrial fibrillation and ventricular arrhythmias—making screening and treatment of OSA a critical component of HCM management. 1
Prevalence and Clinical Impact
The relationship between OSA and HCM is bidirectional and clinically significant:
- OSA prevalence in HCM is dramatically elevated at 55-70%, compared to 15% in general adult men and 5% in women 1, 2, 3
- Patients with HCM and comorbid OSA are typically older, more often hypertensive, have greater symptom burden, and demonstrate reduced exercise capacity 1, 2, 3
Pathophysiologic Consequences
OSA drives multiple adverse pathways in HCM patients:
Cardiac Remodeling and Fibrosis
- Myocardial scar burden (measured by late gadolinium enhancement) increases progressively with OSA severity, from 6.1% in mild OSA to 15.5% in severe OSA 4, 5
- The apnea-hypopnea index (AHI) is independently associated with increased myocardial fibrosis after adjusting for age, sex, and BMI 4, 5
- OSA severity correlates with adverse cardiac remodeling: larger left ventricular end-diastolic diameter, larger left atrial diameter, and paradoxically thinner maximal wall thickness 6
Arrhythmic Complications
OSA substantially increases arrhythmia risk through both direct and AF-mediated pathways:
- Direct effects: OSA is independently associated with isolated PVCs, ventricular bigeminy/trigeminy, non-sustained ventricular tachycardia (NSVT), and supraventricular tachycardia 5
- AF-mediated pathway: OSA increases AF prevalence (OR 1.37), and AF is the dominant mediator (accounting for ~98.5%) of the association between OSA and cardiac arrest/ventricular fibrillation in HCM patients 7, 8
- Both AHI and myocardial fibrosis (LGE%) are independent risk factors for ventricular arrhythmias 5
Hemodynamic and Structural Effects
- Greater likelihood of left ventricular outflow tract obstruction (LVOTO) 1
- Increased left ventricular hypertrophy and mass 1
- Association with heart failure progression 1
Clinical Guideline Recommendations
The 2024 AHA/ACC/Multisociety HCM Guideline provides a Class 1 (Strong) recommendation: In patients with HCM, assessment for symptoms of sleep-disordered breathing is recommended, and if present, referral to a sleep medicine specialist for evaluation and treatment is recommended 1
Key Screening Considerations
Screen all HCM patients for OSA symptoms, particularly those with:
- Obesity (body mass index >25 kg/m²)
- Drug-resistant hypertension
- Atrial fibrillation
- Excessive symptom burden despite optimal HCM therapy
- Reduced exercise capacity
- Nocturia (often misattributed to other causes) 9
Important caveat: Many HCM patients with OSA do not report classic daytime sleepiness, so active screening rather than waiting for patient complaints is essential 10
Clinical Implications for Management
Why This Matters for Morbidity and Mortality
The composite outcome data is compelling: obesity (often associated with OSA) independently predicts death, heart failure, AF, ventricular arrhythmias, and stroke in HCM with hazard ratios of 1.4-1.9 1. While direct mortality data for OSA treatment in HCM is lacking, the mechanistic links through increased fibrosis, arrhythmias, and AF strongly suggest treatment would improve outcomes 1, 2, 3.
Treatment Rationale
Diagnosis and treatment of OSA could:
- Reduce symptom burden and improve exercise capacity
- Decrease arrhythmic complications (particularly AF and ventricular arrhythmias)
- Potentially slow adverse cardiac remodeling and fibrosis progression
- Improve blood pressure control in hypertensive HCM patients
However, systematic clinical trials demonstrating that OSA treatment reduces adverse outcomes in HCM are still needed 1, 2, 3.
Practical Algorithm
- Screen all HCM patients for OSA symptoms at every visit (snoring, witnessed apneas, nocturia, morning headaches)
- Lower threshold for polysomnography in patients with obesity, hypertension, AF, or unexplained symptom burden
- Refer to sleep medicine specialist when OSA symptoms are present (Class 1 recommendation) 1
- Optimize comorbidity management: Treat hypertension preferentially with beta-blockers or non-dihydropyridine calcium channel blockers (which also treat obstructive HCM) 1
- Counsel on weight loss: Comprehensive lifestyle interventions for weight reduction may lower risk of LVOTO, heart failure, and AF 1
The evidence consistently demonstrates that OSA is not merely a comorbidity in HCM but an active contributor to disease progression and adverse outcomes, warranting aggressive screening and treatment.